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A commentary on
Attention to eyes is present but in decline in 2–6-month-old infants later diagnosed with autism
by Jones W, Klin A. Nature (2013) 504:427–31. doi: 10.1038/nature12715
A recent Nature article provided preliminary evidence that infants age 2–6months old, who were
later diagnosed with Autism Spectrum Disorder (ASD), fixated more on the mouth than eyes and
more at objects than people when viewing videos of typical childhood social scenes (1). While the
sample was small, a reliable pattern of decline in eye fixation accurately predicted their level and
classification of symptoms at age three suggesting that – for the first time – an infant could be
assessed within the first 6months of life for their potential of developing ASD (see Table 1 for
studies that used eye-tracking with infants 12months and younger). These eye-tracking devices,
which are currently in clinical trials, could provide access to an affordable and objective tool with
the potential for extremely early intervention. Detecting ASD risk during the first 6months of life
presents unprecedented opportunities to intervene, providing children opportunities to build critical
skills before autistic characteristics fully emerge. Because the eye-tracking device allows for a non-
invasive, portable assessment, the device could also enable pediatricians to provide comparable
screening services globally. With such promise, a near future where infants are placed into an
eye-tracking device at routine pediatric visits is compelling, if not guaranteed.
Autism SpectrumDisorder is characterized by developmental differences and difficulties in social
communication and interaction coupled with repetitive behaviors (7) with an estimated prevalence
of 1 in 68 children in American populations (Developmental Disabilities Monitoring Network
Surveillance Year 2010 Principal Investigators and Centers for Disease Control and Prevention
(CDC) 2014) and a range of 1 in 333 to 1 in 86 among European nations. A global mean of 1 in 160
children (8)makes ASD a public health concernmore prevalent than juvenile cancers (9) or diabetes
(10). Diagnoses are generally made subjectively by assessing behavioral symptoms through parental
interview and behavioral observations of the child (8, 9). Presently, clinicians are unable to reliably
diagnose ASD until 12months using the AutismDiagnostic Observation Schedule (ADOS) Toddler
module (11); however, diagnosis usually happens much later. A 2014 CDC study estimated age at
diagnosis using DSM IV TR classifications, which included several disorders under the category of
ASDs rather than the DSM 5model of ASD as a single diagnosis. It reported 48months as the mean
age of diagnosis for Autistic Disorder, 53months for ASD or Pervasive Developmental Disorder-Not
Otherwise Specified, and 75months for Asperger’s syndrome (12). Widespread recommendations
by professionals for early identification and intervention (8, 13, 14), along with a lack of viable
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TABLE 1 | Eye-tracking studies in high-risk and ASD individuals up to 1 year of age.
Study N Sex (F/M) Age (years) Earliest age
finding (years)
Result Location of
recruitment
Elsabbagh et al. (2) 54 33/21 0.5–0.8 0.7 Infants who attended more to mouths in complex scenes,
regardless of risk for ASD, developed better expressive
language skills
London, UK
Shic et al. (3) 57 17/40 0.5 0.5 Infants later diagnosed with ASD have difficulty attending less
to faces and less to areas of speaker’s faces that would
provide verbal cues
New Haven, CT, USA
Jones and Klin (1) 11 0/11 0.2–2 0.2 Infants later diagnosed with ASD attend more to mouths. Atlanta, GA, USA
Chawarska et al. (4) 49 15/34 0.5 0.5 Infants later diagnosed with ASD attend less attention to
people and faces
New Haven, CT, USA
Elsabbagh et al. (5) 54 3/21 0.5–0.8 n/a Infants, regardless of outcome, attend similarly to faces London, UK
Young et al. (6) 58 26/32 0.5 n/a Infants, regardless of outcome, do not differ in scanning of
complex or simple scenes of eyes, mouths, and hands
Davis, CA, USA
Studies with infants up to 1 year of age are featured. N represents children who are high risk for ASD or ASD who were confirmed prior to or after the testing that were included in the
analysis. Only studies where eye-tracking data could be correlated with a diagnosis of ASD were included.
community systems of long-term care (15), have driven priori-
ties for autism research and funding toward reducing the age of
diagnosis and intervention (16).
Currently, the AmericanAcademy of Pediatrics (AAP) (17) and
the CDC (18) recommend community-wide, routine 18- and 24-
month-old screenings for ASD. Early identification can provide
the opportunity to facilitate early skill development and reduce the
population of children and adults who are reliant on inadequate
community resources for long-term care and opportunities for
community engagement (15, 19).While this tool is in early phases,
it has rapidly moved to clinical trials; ethical concerns must be
considered alongside and as an integral part of the research, not
only for future patients, but also for current study participants.
Importantly, preclinical assessment technologies run the risk of
bearing false negatives, i.e., children not identified as autistic but
who receive an ASD diagnosis at a later age, and false positives,
i.e., children identified as likely to be autistic who are not later
diagnosed with ASD. Parents will undoubtedly want to do some-
thing with a positive screen. Studies have shown that parent’s
uncertainty about their child’s medical diagnosis can lead to poor
coping or adaptation to their child’s condition (20). Conversely,
parents may be overly reassured by the preclinical assessment. For
example, parents whose children receive a negative screen may
assume their child will not develop ASD and miss opportunities
to intervene.
In the event of a false positive, parents might invest in unnec-
essary expensive interventions, surveillance, and treatments as
well as lead to changes in the life trajectories of the child, care-
givers, and entire family. Caregivers may decide to change their
financial plans and reallocate time and material resources to a
child’s early intervention or care. Even after a false positive is
identified, caregivers may be unable to cease looking for signs
of ASD as a child ages or perhaps mistake a positive assessment
with a diagnosis and although there is public recognition of the
importance of ASD identification throughout the world (21),
ASD is often considered an unwanted, even alarming, stigmatized
condition (22, 23). Healthcare providers will need to be able
to advise parents on what parents can do while delivering an
appropriately cautious interpretation of such preclinical testing
results.
We must also consider how clinicians should respond when
parents whose children receive a positive screen inquire about
interventions for their infant given the lack of evidenced based
interventions for infants. Preclinical screens, that assess a pheno-
type that might predict ASD, but is not a key trait of the diagnosis,
such eye-tracking technologies assess risk and are not diagnos-
tic for ASD. This is important to emphasize to everyone from
parents, study participants, and patient schedulers to insurance
companies. Risk can be characterized in terms of both severity
and susceptibility (24). ASD represents a diverse set of symptoms,
abilities, and impairments and a variable timeline of development.
It is unclear how much consistent predictive power preclinical
testing will have for describing specific risks for severity, behav-
ioral profiles, and age of symptom onset. With this ambiguity,
there is significant potential for misunderstanding, resistance to
a preclinical assessment, and damage to the therapeutic alliance
of the families and clinicians.
Further, using a word like “risk” – understood differently
among clinicians and the general public and across cultures –
may not be wholly appropriate (25). The word “risk” may fail to
communicate the vast range of possible phenotypic outcomes and
instead place too much focus on negative outcomes. Adherents
of a growing neurodiversity movement – an advocacy position
that rejects the ideas that autism is unwanted and should be
“cured” and, instead, acknowledges autism as a natural variant
of human neurological development (26; See Box 1 for more on
neurodiversity) – would resist the use of “risk” in relation to ASD
(28). Healthcare providers and parents will need to understand the
meaning of “risk” associated with a positive preclinical assessment
and be able to weigh the potential benefits of treatment against
the consequences of not seeking or participating in recommended
interventions. Detailed communication guidelines need to be
developed and disseminated with this tool alongside a public
health campaign.
While the 2014 US Patient Protection and Affordable Care
Act (ACA) protects against discrimination of pre-existing condi-
tions (29), it remains unclear how such a preclinical “diagnosis”
or “assessment,” which is not a clinically confirmed diagnosis,
would impact life- or long-term-care insurance policies. The US
ACA states that all Marketplace insurance plans, must cover ASD
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BOX 1 | Neurodiversity and this article’s language.
Neurodiversity is a growing advocacy movement that aims to decrease
autism-related stigma by encouraging tolerance of neurological difference
(27, 28). Various strategies are encouraged towards this aim, including
increasing the visibility of autistic individuals throughout communities, more
funding allocation for research focussed on improving the quality of life of
autistic individuals (rather than “curing autism”), and inclusion of autistic
voices in research, policy, and advocacy. Language is an important tool for
neurodiversity. This includes using the phrase “autistic person” rather than
“person with autism” to demonstrate that autism is important to identity (27).
Linguistic models of neurodiveristy also includes a shift from a “language of
deficit” to a “language of difference.” This is done through subtle shifts in
language, such as that in the current article. These linguistic choices serve to
present ASDs or core attributes of ASD as a particular state of being that is
not necessarily considered unwanted or in need of a cure. A discussion of
preclinical detection can imply that preventative interventions must be used
because autism itself is problemantic. However, in our discussion we
advocate that early intervention can ultimately lead to promoting greater
community involvement of autistic individuals rather than “normalizing” or
eradicating autistic individuals. In both the clinical and research domains the
goals and rationale of developing and implementing such technologies will
need to be clearly and thoughtfully described.
screening, which usually consists of a behavioral checklist, for
children at 18 and 24months (30), yet it is unclear how the
ACA would address the much more costly eye-tracking screen-
ing. In addition, only 41 states in the US have passed legislation
requiring some level of insurance coverage for ASD services and
therapies, but these policies rarely cover screenings (31). Many
EU countries follow the recommendations the Royal College of
Paediatrics andChildHealth, the EuropeanCommission of Public
Health, and theUKNational ScreeningCommittee (32, 33), which
discourage community-wide screening (34). The World Health
Organization’s resolution on ASD and recent meeting reports do
not prioritize screening, focusing instead on increasing resources
for autistic individuals and reducing stigma (21, 35). Even with
national health care, most countries are not currently prepared to
reimburse for infant or preclinical screens.
Stakeholders in the ASD community, including professionals,
families, and diagnosed individuals, need to work with public
policy makers, researchers, and clinicians to formulate strategies
and regulations to determine when preclinical assessment should
be performed and who is qualified to interpret and deliver such
assessments (e.g., preclinical counselors, clinical psychologists,
or primary care doctors). Because information about one’s brain
health often feels especially identity forming (36), there must
be safeguards for maintaining privacy of preclinical information.
Without addressing these concerns, these tools, despite their enor-
mous potential for providing opportunities for early intervention
and substantial reduction of individual and societal healthcare
costs, risk losing resources and public support to be fully devel-
oped and advanced.
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